Gryaznov Sergei purchased $3K of MAIA
Gryaznov Sergei (Chief Scientific Officer) purchased 2,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.34 on 2026-06-01.
How this was made
The 30-second read
Why it matters
The disclosure adds sentiment context but does not provide new clinical, regulatory, or financial information.
Market read
Traders may view the purchase as a small positive signal, but the lack of fundamental updates limits trading edge.
What to watch
Check for follow-on Form 4s (size/frequency) and whether the purchase price diverges from recent trading levels; one small buy is not a trend by itself.
Background
The filing is an SEC Form 4 insider transaction: Gryaznov Sergei (Chief Scientific Officer) purchased MAIA shares directly.
Ticker impact
SEC Form 4 shows MAIA’s Chief Scientific Officer bought 2,000 shares open-market at $1.3450 on 2026-06-01.
Likely limited near-term impact; any reaction should fade unless followed by larger buys or fundamental catalysts.
This is an ownership-change filing (Form 4) with a modest dollar amount and no accompanying operational/financial news.
Market effects
Minimal; single-company insider transaction typically does not reset sector expectations.
None indicated.
None indicated.
Counterpoint
Insider purchases can be routine or tax/compensation-related; without a 10b5-1 plan, it still may not signal a new fundamental catalyst.
Key entities
- issuerMAIA Biotechnology, Inc.
Subject of the insider transaction disclosure via SEC Form 4.
- insiderGryaznov Sergei
Chief Scientific Officer who purchased 2,000 shares open-market.
